Omitting axilla lymphadenectomy even by positive sentinel lymph node: A change in breast cancer treatment practice

Women's Health

Volumn 7, Issue 4, 2011, Pages 417-418

  Zoras, Odysseas ^a   Ziogas, Dimosthenis ^b   Roukos, Dimitrios H ^b,c  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

breast cancer; evidence; medical practice; mortality; screening mammography

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAL PRACTICE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SAFETY; PATIENT SELECTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SENTINEL LYMPH NODE; SURVIVAL TIME; TREATMENT PLANNING;

EID: 79960946687     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.46     Document Type: Article

References (4)

1. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6), 569-575 (2011).
2. Caudle AS, Hunt KK, Kuerer HM et al. Multidisciplinary considerations in the implementation of the findings from the American college of surgeons oncology group (ACOSOG) Z0011 study: a practice-changing trial. Ann. Surg. Oncol. DOI: 10.1245/s10434-011-1593-7 (2011) (Epub ahead of print).
3. King TA, Sakr R, Patil S et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J. Clin. Oncol. 29(16), 2158-2164 (2011).
4. Green ED, Guyer MS, National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature 470(7333), 204-213 (2011).